Cosmetic Surgery & Aesthetic MedicineGold report

Published May 2026Insight Research25 min read2026 Edition15 sources, 15 primary-gradeVery high source depth

Thailand Cosmetic Surgery & Aesthetic Medicine Market Intelligence

Thai cosmetic surgery and aesthetic medicine reached THB 76.5B in 2025 (Kasikorn Research). Hospital cluster (BDMS, Yanhee, Bumrungrad, BPH, MedPark, Phyathai 2) anchors surgical and inbound; ~7,000 aesthetic clinics (Wuttisak, Apex, Pongsak, Nida) run device-led non-invasive. Gender-affirming surgery (Yanhee, Suporn, Kamol, PAI) is an internationally recognised niche.

Key takeaways

1
Thai cosmetic surgery and aesthetic medicine reached an estimated (~) in 2025 per Kasikorn Research (+ YoY); Grand View Research projects CAGR on the 2023 device-and-procedure baseline.
2
Operator landscape splits into three tiers: JCI-accredited hospitals (BDMS, Bumrungrad, MedPark, Samitivej), dedicated cosmetic-surgery hospitals (Yanhee, BPH, Phyathai 2), and ~7,000 aesthetic clinics (Wuttisak, Apex, Pongsak, Nida, Rajdhevee).
3
Procedure mix has shifted decisively to non-invasive: aesthetic devices (Hydrafacial, Pico laser, Thermage, Ultherapy) now ~ and injectables (botulinum, fillers, threadlift) ~; surgical cosmetic only ~ of revenue but a higher share of medical-tourism receipts.
4
Gender-affirming surgery (GAS) remains an internationally recognised Thai specialty anchored by Yanhee, Suporn (Chonburi), Kamol, Preecha Aesthetic Institute (PAI), Chettawut, and Sanguan (Phuket); ~ of revenue but disproportionate international brand.
5
Patient source mix is rebalancing: Chinese inbound recovered but below 2018 peak; GCC, Australia, US, and Europe expanding; the LTR Long-Term Resident visa supports wellness-medical residency for high-income foreigners.
6
Our read: Thailand holds the structural cost-quality lead in Asia for body and gender-affirming surgery; Korea wins facial and rhinoplasty. The 2025-2030 growth case is device-led non-invasive plus BDMS Laguna Phuket wellness-medical complex, not surgical volume.

Executive summary

Thailand's cosmetic surgery and aesthetic medicine market reached an estimated (~) in 2025 per Kasikorn Research, a year-over-year increase from in 2024. Grand View Research anchors the procedures-and-devices market at in 2023 with an CAGR to 2030, while the Thai Medical Hub Board's -by-2027 projection implies a more aggressive trajectory that bakes in inbound medical tourism, longevity medicine, and aesthetic-device pull. The sector recovered to roughly of its 2018 peak in foreign-patient throughput by 2024-2025 with approximately international patients across private hospitals.^{[, , ]}

The operator landscape splits into three structurally distinct tiers. JCI-accredited general hospitals (BDMS, Bumrungrad, MedPark, Samitivej) run the inbound surgical line through dedicated aesthetic centres — Bangkok Hospital aesthetic, Esperance Aesthetic Clinic at Bumrungrad, BDMS Wellness Clinic, and the planned Laguna Phuket complex. Dedicated cosmetic-surgery hospitals (Yanhee ~600 beds, Bangkok Plastic Surgery, Phyathai 2) anchor the volume tier. A long tail of approximately 7,000 aesthetic clinics — Wuttisak, Apex, Pongsak, Nida Skin, Rajdhevee — runs the non-invasive device and injectables segment across Bangkok, Phuket, Pattaya, and Chiang Mai.^{[, , , ]}

Procedure mix is the most important strategic shift this decade. Non-invasive aesthetic devices (Hydrafacial, Pico laser, Thermage, Ultherapy) now account for an estimated of revenue, with injectables (botulinum toxin, dermal fillers, threadlift) at . Surgical cosmetic procedures — rhinoplasty, eyelid surgery, breast augmentation, and reduction — sit at approximately of revenue but a higher share of inbound medical-tourism receipts. Gender-affirming surgery, internationally recognised through Yanhee, Suporn, Kamol, and Preecha Aesthetic Institute (PAI), represents roughly of revenue but carries disproportionate global brand weight.^{[, , ]}

Source-country mix is rebalancing materially. Chinese inbound recovered but remains below its 2018 peak; BDMS reported international-patient revenue growth in FY2024 with high-complexity cases led by Qatar and China. GCC, Australia, US, and Western Europe are expanding, supported by the LTR Long-Term Resident visa for wellness-medical residency. Korean competition is the binding external variable: Korea crossed 130,000 aesthetic patients in 2024 (+ YoY) and continues to dominate facial and rhinoplasty positioning; Thailand keeps the cost lead on body procedures, gender-affirming surgery, and recovery-friendly destinations (Phuket, Pattaya, Hua Hin).^{[, , ]}

Kasikorn Research, Grand View Research, US ITA, BDMS and Bumrungrad 56-1, Yanhee, TransHealthcare, BOI LTR.

Data as of: 2025E full-year

Thai cosmetic surgery and aesthetic medicine market size (THB billion, 2020-2025E)

2020

Size (THB B)

YoY

-12%

Context

COVID trough; inbound medical tourism collapse.

2021

Size (THB B)

YoY

+5%

Context

Thai-domestic resilience; injectables and non-invasive devices held up.

2022

Size (THB B)

YoY

+10%

Context

Reopening; ASEAN and Western inbound returning.

2023

Size (THB B)

YoY

+11%

Context

USD 1.46B Grand View baseline; Chinese inbound partial recovery.

2024

Size (THB B)

74.4

YoY

+5%

Context

BDMS +11% international revenue; aesthetic devices accelerated.

2025E

Size (THB B)

76.5

YoY

+2.8%

Context

Kasikorn Research headline; growth moderates as inbound normalises.

Year	Size (THB B)	YoY	Context
2020	55	-12%	COVID trough; inbound medical tourism collapse.
2021	58	+5%	Thai-domestic resilience; injectables and non-invasive devices held up.
2022	64	+10%	Reopening; ASEAN and Western inbound returning.
2023	71	+11%	USD 1.46B Grand View baseline; Chinese inbound partial recovery.
2024	74.4	+5%	BDMS +11% international revenue; aesthetic devices accelerated.
2025E	76.5	+2.8%	Kasikorn Research headline; growth moderates as inbound normalises.

Kasikorn Research 2025, Grand View Research, BDMS 56-1, analyst estimates.

Data as of: 2025 estimated

Procedure mix (% of FY2025E revenue)

Non-invasive aesthetic devices (laser, RF, HIFU)

Share %

32%

Notes

Hydrafacial, Pico laser, Thermage, Ultherapy; clinic-chain led.

Injectables (botulinum, fillers, threadlift)

Share %

24%

Notes

Highest-frequency procedure; recurring 3-12 month cadence.

Surgical cosmetic (rhinoplasty, eyelid, breast)

Share %

22%

Notes

Higher share of inbound medical-tourism receipts.

Liposuction, body contouring

Share %

10%

Notes

Including CoolSculpting, Emsculpt non-invasive body devices.

Gender-affirming surgery, specialty

Share %

Notes

Yanhee, Suporn, Kamol, PAI, Chettawut, Sanguan.

Hair transplant, scalp aesthetics

Share %

Notes

FUE-led; growing male-buyer segment.

Segment	Share %	Notes
Non-invasive aesthetic devices (laser, RF, HIFU)	32%	Hydrafacial, Pico laser, Thermage, Ultherapy; clinic-chain led.
Injectables (botulinum, fillers, threadlift)	24%	Highest-frequency procedure; recurring 3-12 month cadence.
Surgical cosmetic (rhinoplasty, eyelid, breast)	22%	Higher share of inbound medical-tourism receipts.
Liposuction, body contouring	10%	Including CoolSculpting, Emsculpt non-invasive body devices.
Gender-affirming surgery, specialty	7%	Yanhee, Suporn, Kamol, PAI, Chettawut, Sanguan.
Hair transplant, scalp aesthetics	5%	FUE-led; growing male-buyer segment.

Grand View Research, Krungsri medical-devices outlook, operator disclosures.

Data as of: 2025 estimated

Analyst framing

Why this report

Thai cosmetic surgery and aesthetic medicine is a $2.22B sector running across three structurally different operator tiers. The surgical-hospital cluster takes the headline brand; the device-led clinic chains take the volume; gender-affirming surgery takes the international reputation. Buyers need a clear map of each tier, the source-country shift, and where Korean competition cuts deepest.

Operator playbooks

BDMS (SET: BDMS): Thailand's largest hospital group runs cosmetic and aesthetic through Bangkok Hospital aesthetic centre, BDMS Wellness Clinic (Bangkok and Phuket), and Phyathai-Paolo network. FY2024 international-patient revenue grew approximately 11% on high-complexity cases from Qatar and China. The planned Laguna Phuket wellness-medical complex pivots BDMS into longevity medicine, regenerative therapies, and integrated aesthetic stays — the structural growth case for the group, not surgical volume.

Bumrungrad Hospital (SET: BH): premium JCI brand with Esperance Aesthetic Clinic and Vitallife Wellness within the international-patient hospital. Strategic positioning is high-acuity, high-margin, and discretionary; aesthetic and cosmetic surgery is a measurable but undisclosed share of revenue. Bumrungrad serves the wealthiest GCC, Chinese, and Western inbound segments where price sensitivity is low and surgeon brand matters most.

Yanhee International Hospital (private): the largest dedicated cosmetic-surgery hospital with approximately 600 beds and 75,000+ annual patients from 162 countries. Mass-market positioning makes Yanhee the volume anchor for international cosmetic tourism, with deep gender-affirming surgery practice. The Yanhee package model (all-inclusive with hotel-style recovery) is the template most international comparison platforms benchmark to.

Bangkok Plastic Surgery (BPH Aesthetic, private): specialist cosmetic and plastic-surgery hospital focused on rhinoplasty, breast aesthetic, and body contouring. Mid-premium positioning between Yanhee mass-market and Bumrungrad premium. Strategic differentiator is surgeon brand and the depth of Korean-trained rhinoplasty practitioners.

Phyathai 2 Hospital (BDMS): the cosmetic clinic line runs within BDMS Phyathai-Paolo network. Mid-premium positioning, Bangkok metro catchment, with stronger Thai-domestic share than Bumrungrad or Bangkok Hospital. Operates as the BDMS aesthetic mid-tier with referral pipelines from the wider Phyathai-Paolo hospital network.

MedPark Hospital (private): newer Bangkok premium hospital with a deliberate cosmetic and aesthetic positioning. Markets itself heavily to inbound medical tourists with package-priced cosmetic procedures and integrated wellness stays. Competitive vector against Bumrungrad and Bangkok Hospital for the high-end international segment.

Aesthetic clinic chains (Wuttisak, Apex Medical Center, Pongsak, Nida Skin, Rajdhevee, Romrawin): the non-invasive device segment runs across ~7,000 clinics (2,000 Bangkok, 5,000 provincial). Apex was founded 1995 with 42+ branches; Pongsak runs ~9 to 50 branches across Thailand. These chains operate on a franchise or directly-managed model with imported device technology (Hydrafacial, Pico laser, Thermage, Ultherapy) and recurring injectables visits.

Gender-affirming surgery cluster: Yanhee (Bangkok), Suporn Clinic (Chonburi), Kamol Hospital (Bangkok), Preecha Aesthetic Institute / PAI (Bangkok), Chettawut Plastic Surgery Center (Bangkok), Sanguan Aesthetic (Phuket). Six primary clinics handle the bulk of international GAS volume; Thai surgical pedigree dates to Dr. Preecha Tiewtranon's work from the 1980s. International patients come predominantly from Australia, US, and Western Europe; pricing typically USD 12,000-25,000 for primary procedures versus USD 30,000-80,000 in the US.

Operator concentration (FY2025E revenue share estimate)

Aesthetic clinic chains (Wuttisak, Apex, Pongsak, Nida, Rajdhevee)

Share %

28%

Kind

Clinic chain

Notes

~7,000 aesthetic clinics; device and injectables driven.

Bangkok Dusit Medical Services (BDMS)

Share %

18%

Kind

Listed hospital

Notes

Bangkok Hospital aesthetic, BDMS Wellness, Phyathai-Paolo.

Single-doctor clinics, other hospitals

Share %

17%

Kind

Long tail

Notes

Independent surgeons; provincial and Phuket cluster.

Yanhee International Hospital

Share %

14%

Kind

Private hospital

Notes

Largest dedicated cosmetic hospital; ~600 beds.

Bumrungrad Hospital

Share %

Kind

Listed hospital

Notes

Esperance Aesthetic, Vitallife; premium tier.

Bangkok Plastic Surgery (BPH Aesthetic)

Share %

Kind

Private hospital

Notes

Specialist cosmetic and plastic surgery.

Phyathai 2 Hospital

Share %

Kind

Listed hospital (BDMS)

Notes

BDMS-affiliated mid-premium cosmetic clinic.

Nirunda International Aesthetic

Share %

Kind

Premium clinic

Notes

Standalone non-invasive specialist.

Operator	Share %	Kind	Notes
Aesthetic clinic chains (Wuttisak, Apex, Pongsak, Nida, Rajdhevee)	28%	Clinic chain	~7,000 aesthetic clinics; device and injectables driven.
Bangkok Dusit Medical Services (BDMS)	18%	Listed hospital	Bangkok Hospital aesthetic, BDMS Wellness, Phyathai-Paolo.
Single-doctor clinics, other hospitals	17%	Long tail	Independent surgeons; provincial and Phuket cluster.
Yanhee International Hospital	14%	Private hospital	Largest dedicated cosmetic hospital; ~600 beds.
Bumrungrad Hospital	9%	Listed hospital	Esperance Aesthetic, Vitallife; premium tier.
Bangkok Plastic Surgery (BPH Aesthetic)	6%	Private hospital	Specialist cosmetic and plastic surgery.
Phyathai 2 Hospital	5%	Listed hospital (BDMS)	BDMS-affiliated mid-premium cosmetic clinic.
Nirunda International Aesthetic	3%	Premium clinic	Standalone non-invasive specialist.

Kasikorn Research, operator disclosures, analyst estimates.

Data as of: 2025 estimated

Unlock the full report

Operator playbooks, patient-source mix, regulation, Korean-competition framework, market scenarios to 2031, and recommended actions for operators, investors, and inbound tourism strategists.

Unlock full report·$299-$349

Need more than the web report? Ask for a scoped export or source appendix.

Every report keeps visible citations and source metadata. Terms.

Related reports

Cosmetic Surgery and Aesthetic Tourism: The Korean-Adjacent Bangkok Cluster

Thailand's cosmetic-surgery and aesthetic-medicine industry sized at THB ~76.5B forecast 2025 (+2.8% YoY, ArokaGO), part of broader Thai medical, wellness tourism worth USD ~31.5B in 2024 (Global Market Insights), projected to triple by 2034 at ~13% CAGR. Channel split: clinics ~85% of market value (Bangkok aesthetic-clinic dense cluster on Sukhumvit, Phloen Chit, Thonglor), hospitals ~15% (Yanhee, Bumrungrad, BDMS-Phyathai 2, BPH Aesthetic, Samitivej, BNH). 79% of procedures are surgical, up from 75% in 2022 thanks to safer technology and shorter-recovery techniques. Foreign-patient arrivals to Thai private hospitals reached ~3M in 2024-2025. Cosmetic surgery is the #2 most popular medical service for international patients (top markets: China, Malaysia, Japan). Procedure mix: facial injectables (Botox, fillers; ~25-30% by value), rhinoplasty (Korean-style high bridge), breast augmentation, reduction, liposuction, body contouring, gender-affirming surgery (GRS, SRS), hair transplant FUE. Patient mix: ~50-55% Thai-domestic, ~20-25% Chinese-inbound (recovery from 2020-2022 trough), ~10-15% ASEAN regional, ~10-15% Western. GRS, SRS specialty: PAI (Preecha Aesthetic Institute, 6,000+ procedures since 1980), Kamol Hospital, Suporn (Pattaya), Chettawut, Sanguan (Phuket), Yanhee primary clinics; 100+ qualified surgeons; total packages USD 10,000-25,000 vs 3-4x in US, UK. Pricing 30-50% below Singapore, Hong Kong; 70-85% below US, UK. Korean-trained surgeons increasingly common; K-Beauty aesthetic positioning durable. Structural read: cosmetic-tourism resilient; Chinese-inbound recovery tailwind; GRS, SRS niche maintains international leadership.

Open report →

Thailand Hair Transplant FUE & Aesthetic Medical Tourism 2027 Market Intelligence

Bangkok aesthetic medical-tourism market — hair transplant FUE/DHI, scalp PRP, beard and eyebrow restoration, plus aesthetic-adjacent botox, filler, thread-lift — is on track to reach USD 1.4-2.6B in 2027 (vs USD 380-680M 2024) driven by cost arbitrage (Thai THB 30-65 per graft vs Turkey EUR 1-3, Korea USD 5-12, USA USD 10-25), Korean-medical-tourism-fatigue, LTR retiree demand, and Bumrungrad/BDMS aesthetic cross-sell. Absolute Hair Clinic, Hairsmith, Yanhee, BAAC, Nirunda, Forhair Bangkok anchor the operator cohort with Bumrungrad and BDMS on the institutional side.

Open report →

Thailand Hospital Group Consolidation Deep Dive

Deep-dive into Thai hospital group consolidation. Listed hospital operators: BDMS (SET: BDMS, largest — Bumrungrad, Samitivej, BPH, 50+ hospital network), Bumrungrad International (SET: BH, direct listing), Bangkok Chain Hospital (SET: BCH — World Medical, WMC), Chularat (SET: CHG — eastern corridor, industrial-estate), Principal Healthcare (SET: PRINC — provincial consolidator), Thonburi Healthcare (SET: THG), Praram 9 (SET: PR9 — cardiac, oncology specialty), Ramkhamhaeng Hospital (SET: RAM — listed federation of Ramkhamhaeng-brand hospitals). M&A track record: BDMS roll-up of Samitivej, Paolo, BPH, regional provincial; PRINC provincial network consolidation; THG Thonburi expansion; BCH World Medical, WMC acquisitions. Drivers: aging Thai population (20%+ >65 by 2030), rising private-pay, SSO, UCS volume, medical tourism scale, international-insurer integration. EBITDA margins: urban tier-1 JCI-accredited ~30-40%; provincial tier-2 ~15-25%; rural tier-3 ~10-15%. Pillar Two (2025+), Thai Medical Council foreign-physician restriction, workforce cap shape economics.

Open report →

Thai Medical Tourism: Acuity Mix and the International-Cohort Recovery

Thai medical tourism splits cleanly across acuity tiers: high-acuity cardiology, oncology and orthopaedics (Middle East and CLMV led, ~38% of international revenue), mid-acuity cosmetic and gynaecology (~26%), wellness, IVF and executive (~20%), and dental, check-up and day-case (~16%). BDMS, Bumrungrad and Bangkok Chain Hospital capture the bulk of high-spend international flow at JCI-accredited price points roughly 30-50% below US, UK and Singapore equivalents, with the 2024 recovery led by the Middle East cohort while Chinese flow recovers more slowly.

Open report →